Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
PharmaNutra S.p.A. is an Italian pharmaceutical and nutraceutical company specializing in the research, development, production, and marketing of innovative nutritional supplements and medical devices. Headquartered in Pisa and founded in 2003, it is renowned for its leadership in iron-based supplements under the SiderAL® trademark, utilizing patented Sucrosomial® Technology to treat iron deficiencies and support immune health, with over 130 published scientific papers validating efficacy. The company also offers products for joint health via the Cetilar® brand, pregnancy nutrition, muscle and joint support, sports nutrition, ophthalmic care, and night rest solutions, alongside raw materials and bioimpedance analysis devices through its Akern subsidiary. With 118 employees, PharmaNutra distributes domestically via over 160 medical representatives to pharmacies and parapharmacies, and internationally to more than 60 countries through 40 partners, focusing on Europe, the Middle East, South America, and the Far East. Its commitment to proprietary raw materials, patents, and clinical data underscores its role in advancing healthcare and wellness solutions. Key figures include Chairman and CEO Andrea Lacorte and COO Carlo Volpi. PharmaNutra S.p.A. plays a vital part in the healthcare sector, particularly in specialty pharmaceuticals and nutraceuticals.
Margins and capital returns are both well above average: 22.77% operating margin, ROIC at 22.41%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 13.8%, still solid.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€140M
▲ +13.8% YoY
Net Income (TTM)
€21M
▲ +20.3% YoY
Op. Margin
22.62%
▼ -1.1pp YoY
ROIC
22.41%
▲ +2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€16M
▲ +1.1% YoY
Op. Cash Flow (TTM)
€18M
▲ +1.1% YoY
Net Debt
-€10M
Net Cash Position
Cash & Equiv.
€31M
3Y CAGR: +16.8%
Continue Research